Searched for
NEW DIABETES TREATMENTS
India emerges as AI opportunity hub, but UN panel warns of gaps in infrastructure, talent and safeguardsA UN-backed panel's initial report highlights India's AI healthcare successes but warns of a growing 'AI divide'. While India possesses tal...- My wife and I declared diabetes in our health insurance policy. Will it cover new illnesses too?ET Wealth Reader's Query: My wife and I have had a floater health insurance policy for over four years. We declared diabetes as a pre-exist...
- Should they now be part of a long-term investing framework? 7 healthcare stocks with upside potential of up to 25%India’s healthcare market may grow steadily, but hospital chains can grow faster as formalisation continues. Healthcare is all about market...
- Healthcare demand is outstripping supply in Noida, says MOFSL; prefers Medanta, Max HealthcareNoida-Greater Noida is rapidly becoming a prime healthcare hub in North India, fueled by population growth and corporate expansion. Despite...
- Scanning cancer, up close & personal: A revolution is underway in cancer diagnosisA gene-based test called next-generation sequencing can identify precise mutations, which can then be treated with targeted therapies. Sinc...
- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...
- A new nanotech breakthrough could help heal dangerous wounds antibiotics can’t treatScientists are using nanomaterials to heal stubborn wounds that resist antibiotic treatment through a new era of smart wound care. These li...
- How many Americans can afford high-quality healthcare? A new poll finds the number has fallenAmericans face growing challenges affording healthcare. New data reveals a significant drop in those able to manage medical costs and acces...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 27%As the market seems to be in comeback mode, it helps to be aware that the best (and probably biggest) wealth creator of the last couple of ...
- These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...
- 5 mid-cap stocks from different sectors with an upside potential of 13 to 24% in one year, according to analystsWhen mid-caps were rising, every concern on valuation was treated as unnecessary caution. Investors who advised patience were told they wer...
- US stocks: Lilly shares rise on hopes that next-gen drug will extend lead in weight-loss marketLilly presented full data from two retatrutide trials, one in treatment naive type 2 diabetes patients and another in patients with obesity...
- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- Alkem rolls out single-shot semaglutide syringes at Rs 350 for diabetes, weight lossAlkem Laboratories has launched semaglutide in single-shot pre-filled syringes in India. This makes treatment more accessible and affordabl...
- Good news for diabetes & BP patients: Govt cuts prices of these 30 medicines, relief may reach pharmacies soonThe National Pharmaceutical Pricing Authority (NPPA) has fixed retail prices for 30 essential drug formulations, including those for diabet...
- “Not Australia, but India rejected me for being a woman”: Kiran Mazumdar-Shaw clarifies how gender bias led her to build Biocon in viral postBiocon founder Kiran Mazumdar-Shaw intervened and clarified after a viral post claimed that Australia denied her a master brewer role due t...
- What if chronic nerve pain isn’t just something to block, but something to fix at the cellular level? New study reveals potential way to “recharge” nerve cells to relieve long-term painScientists are exploring a new way to treat chronic nerve pain by focusing on mitochondria, the energy-producing parts of cells. Researcher...
- 2-hour hospitalisation: What health insurance policies really cover and what they excludeNew health plans cover treatments requiring two hours of hospitalisation, but exclusions remain critical.
- Why are Indians suddenly buying more vitamins after starting Ozempic-like weight loss drugs?Demand for vitamin and nutritional supplements is surging in India. This trend follows the increased availability of semaglutide-based weig...
- Dr Reddy's launches oral semaglutide biosimilar Obeda in IndiaDr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...
Load More
